Caris Life Sciences (CAI) EBIT (2024 - 2026)

Caris Life Sciences' EBIT history runs 3 years deep, the most recent figure standing at $5.3 million for Q1 2026.

• In Q1 2026, EBIT rose 109.11% year-over-year to $5.3 million; the TTM figure through Mar 2026 stood at $108.3 million (up 148.62% YoY), while the FY2025 annual figure was $45.1 million, up 117.55% from the prior year.
• EBIT for Q1 2026 stood at $5.3 million, down from $88.4 million in the prior quarter.
• The five-year high for EBIT was $88.4 million in Q4 2025, with the low at -$67.0 million in Q2 2024.
• The 3-year median for EBIT is -$27.5 million (2024), against an average of -$14.3 million.
• Peak annual rise in EBIT reached 338.65% in 2025, while the deepest fall reached 73.16% in 2025.
• Caris Life Sciences' EBIT stood at -$37.0 million in 2024, then surged by 338.65% to $88.4 million in 2025, then plunged by 94.03% to $5.3 million in 2026.
• Business Quant data shows CAI's EBIT at $5.3 million in Q1 2026, $88.4 million in Q4 2025, and $32.6 million in Q3 2025.